title: Why valganciclovir should not be indicated for liver recipients and high-dose acyclovir should not be removed from international cytomegalovirus guidelines.
authors: Andre C
authors: AC
authors: Kalil
authors: Diana F
authors: DF
authors: Florescu
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage; D000075202:Contraindications; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D016031:Liver Transplantation; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir; D000212:Acyclovir